Please check your internet connection and try again.
# Methylcobalamin
## Overview
Methylcobalamin is a biologically active form of Vitamin B12 (cobalamin). Unlike cyanocobalamin, it does not require conversion by the liver to become active and is a cofactor for methionine synthase, which converts homocysteine to methionine.
## Primary Indications
* Peripheral neuropathy (diabetic or toxic).
* Megaloblastic anemia due to Vitamin B12 deficiency.
* Adjunctive therapy for nerve damage/neuritis.
## Adult Dosing
* **Peripheral Neuropathy:** 1500 mcg orally daily, divided into three doses (500 mcg TID).
* **Deficiency/Anemia:** Dosages vary significantly by severity and route. Oral maintenance studies often utilize 1000–1500 mcg daily.
* **Note:** Dosing is highly dependent on institutional protocols and clinical goals (e.g., neuropathy vs. severe deficiency).
## Pediatric Dosing
* **Established Dosing:** No standardized pediatric dosing exists for methylcobalamin-specific formulations. Use age-appropriate cyanocobalamin dosing guidelines if replacing Vitamin B12; otherwise, exercise extreme caution and consult pediatric specialist guidelines.
## Dose Adjustments
* **Renal Impairment:** No formal dosage adjustments required, though patients with chronic kidney disease may have altered requirements.
* **Hepatic Impairment:** Methylcobalamin is preferred in severe hepatic impairment where conversion of cyanocobalamin may be compromised.
## Contraindications
* Hypersensitivity to cobalt or any component of the preparation.
* Leber's hereditary optic neuropathy (administration may cause rapid optic atrophy).
## Adverse Effects
* **Common:** Injection site reactions (if IM), mild diarrhea, nausea, headache.
* **Rare:** Anaphylaxis, rash, pruritus.
## Key Drug Interactions
* **Chloramphenicol:** May decrease the hematopoietic response to Vitamin B12.
* **Proton Pump Inhibitors/H2 Blockers/Metformin:** May impair the absorption of oral Vitamin B12; monitoring of serum levels is recommended with long-term use.
## Monitoring
* Serum Vitamin B12 levels.
* Complete Blood Count (CBC) and Reticulocyte count (if treating megaloblastic anemia).
* Resolution of neurological symptoms (subjective assessment).
* Potassium levels (in the early phase of treating severe megaloblastic anemia due to the risk of hypokalemia).
## Clinical Pearls
* **Bioavailability:** Methylcobalamin can be absorbed via passive diffusion in addition to the traditional intrinsic factor-mediated pathway, which may be beneficial in patients with malabsorption syndromes.
* **Stability:** Protect from light; methylcobalamin is light-sensitive and can degrade if exposed to prolonged UV radiation.
* **Efficacy:** While widely used for neuropathy in some regions (particularly in Asia), large-scale clinical trials supporting routine use for non-deficiency-related neuropathy remain heterogeneous; individual response should be evaluated after 2–3 months of therapy.
***
**Educational Disclaimer:** This information is for educational purposes only. Clinical practice varies by region and institution. Always verify dosages, contraindications, and drug interactions against current primary literature and local clinical protocols before prescribing or administering medication.
